SLC29A1 and acute myeloid leukemia: It has been proposed that a reduced ENT1 expression, together with the upregulation of inactivating enzymes of cytarabine, especially CDA, can predict a worse treatment outcome in AML, irrespective of cytogenetic and molecular risk groups [4].